E Dotor
Overview
Explore the profile of E Dotor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
59
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carrato A, Benavides M, Massuti B, Ferreiro-Monteagudo R, Garcia Alfonso P, Falco E, et al.
BMC Cancer
. 2019 Jun;
19(1):533.
PMID: 31159765
Background: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line...
2.
Vera R, Dotor E, Feliu J, Gonzalez E, Laquente B, Macarulla T, et al.
Clin Transl Oncol
. 2016 Nov;
18(12):1172-1178.
PMID: 27896637
Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit...
3.
Pericay C, Serra-Aracil X, Ocana-Rojas J, Mora-Lopez L, Dotor E, Casalots A, et al.
Clin Transl Oncol
. 2015 Oct;
18(7):666-71.
PMID: 26497352
Purpose: Preoperative chemoradiotherapy and local excision via transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer achieve promising results in selected patients. We describe our long-term follow-up experience with this combination,...
4.
Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M, Manzano J, et al.
Eur J Cancer
. 2015 May;
51(11):1371-80.
PMID: 25963019
Background: Frail elderly patients with metastatic colorectal cancer (mCRC) are not candidates for chemotherapy. Monotherapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies may be an option for these patients...
5.
Pericay C, Lopez A, Soler J, Bonfill T, Dotor E, Saigi E
Clin Transl Oncol
. 2009 Feb;
11(2):114-6.
PMID: 19211378
Oxaliplatin has been classified as an irritant drug. Less than 10 cases of oxaliplatin extravasation through a central venous access have been described to date. We present a case of...
6.
Majem M, Galan M, Perez F, Munoz M, Chicote S, Soler G, et al.
Clin Transl Oncol
. 2007 Dec;
9(12):784-8.
PMID: 18158982
Objective: To provide an outpatient facility to improve the management of chemotherapy toxicity in cancer patients. Patients And Methods: We set up an oncology acute toxicity unit (OATU) to improve...